Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Macbecin SCHEMBL443301 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL2682391 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL2682389 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL12800037 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL2682394 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL13040915 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Macbecin SCHEMBL13040899 | 1.00 | HSP90AA1 (0.77) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL25344099 | 0.95 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL29420374 | 0.95 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA | |
| Herbimycin SCHEMBL21578242 | 0.95 | HSP90AA1 (0.86) | HSP90AA1ALDH1A1ERBB2HSP90AB1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-08-04 | — | — | US | claimed |
| EP-3980563-A2 | NTRK FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | SECURA BIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | TWELVE THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4585268-A2 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | Twelve Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197400-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | INTEILIKINE LLC | 2025-06-19 | — | — | US | disclosed |
| US-20250171453-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-3350183-B1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2025-04-02 | — | — | EP | disclosed |
| US-12213983-B2 | Treatment of cancers using PI3 kinase isoform modulators | INFINITY PHARMACEUTICALS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| CN-105682658-B | Cancer therapy using PI3 kinase subtype modulators | 无限药品公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114230571-A | Solid forms of isoquinolinones, methods of making, compositions containing, and methods of use thereof | 无限药品股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| EP-3964507-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | disclosed |
| WO-2022019920-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | VERASTEM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| US-8669289-B2 | Methods and compositions relating to hematologic malignancies | THE JACKSON LABORATORY (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120114605-A1 | METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES | THE JACKSON LABORATORY | 2012-05-10 | — | — | US | disclosed |
| WO-2010124283-A2 | METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES | THE JACKSON LABORATORY (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220243280-A1 | NTRK FUSION MOLECULES AND USES THEREOF | NTRK1, NTRK3, NTRK2 | HSP90AA1 1786/4885ALDH1A1 4003/4885ERBB2 23/4885 |
| US-12213983-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3CA, MCL1, PIK3CB | HSP90AA1 1153/4885ALDH1A1 2702/4885ERBB2 77/4885 |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | HSP90AA1 3308/4885ALDH1A1 4436/4885ERBB2 598/4885 |
| US-12605387-B2 | Treatment of cancers using PI3 kinase isoform modulators | PIK3R5, PIK3R4, PIK3CD | HSP90AA1 2672/4885ALDH1A1 4700/4885ERBB2 309/4885 |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | HSP90AA1 1629/4885ALDH1A1 3647/4885ERBB2 632/4885 |
| US-20250197400-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | PIK3CA, PIK3CD, PDPK1 | HSP90AA1 1718/4885ALDH1A1 3088/4885ERBB2 749/4885 |
| US-20250319091-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | HSP90AA1 1153/4885ALDH1A1 2702/4885ERBB2 77/4885 |
| US-20250171453-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HSP90AA1 1038/4885ALDH1A1 3154/4885ERBB2 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.